Table 4.

Response rate in relapsed/refractory MCL patients receiving idelalisib

Category	All patients (N = 40)	Receiving <150 mg bid* (n = 24)	Receiving ≥150 mg qd† (n = 16)
ORR	16 (40)	5 (21)	11 (69)
CR	2 (5)	0	2 (12.5)
PR	14 (35)	5 (21)	9 (56.3)
SD	19 (47.5)	15 (62.5)	4 (25)
PD	4 (10)	4 (16.7)	0
NE	1 (2.5)	0	1/16 (6.3)

Data are presented as number (%) of patients.

bid, twice daily; CR, complete response; NE, not evaluable; PR, partial response; qd, daily.

^*Dose cohorts include 150 mg daily, 150 mg twice daily × 21 days, 50 mg twice daily, and 100 mg twice daily.

^†Dose cohorts include 300 mg daily, 150 mg twice daily, 200 mg twice daily, and 350 mg twice daily.